Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 6/20 | 0.80 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.80 |
| ▸ | TSHR | P16473 | 2/20 | 0.80 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.80 |
| ▸ | POLB | P06746 | 1/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.80 |
| ▸ | MAPT | P10636 | 1/20 | 0.80 |
| ▸ | RECQL | P46063 | 1/20 | 0.80 |
| ▸ | BLM | P54132 | 1/20 | 0.80 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.80 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.80 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.80 |
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.54 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.54 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | CES2 | O00748 | 2/20 | 0.48 |
| ▸ | CES1 | P23141 | 2/20 | 0.48 |
| ▸ | DAO | P14920 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzamide SCHEMBL3541486 | 0.90 | PARP1 (0.80) | PARP1TDP1TSHRCYP2C19POLB | |
| Benzamide SCHEMBL29618402 | 0.89 | — | — | |
| Benzamide SCHEMBL30112947 | 0.89 | PARP1 (1.00) | PARP1TDP1TSHRCYP2C19POLB | |
| Benzamide SCHEMBL27963599 | 0.89 | PARP1 (1.00) | PARP1TDP1TSHRCYP2C19POLB | |
| Benzamide SCHEMBL16352 | 0.89 | — | — | |
| Benzamide SCHEMBL6690447 | 0.89 | PARP1 (1.00) | PARP1TDP1TSHRCYP2C19POLB | |
| Benzamide SCHEMBL1222101 | 0.89 | PARP1 (1.00) | PARP1TDP1TSHRCYP2C19POLB | |
| Benzamide SCHEMBL1332331 | 0.89 | — | — | |
| SCHEMBL21755166 | 0.89 | PARP1 (1.00) | PARP1TDP1TSHRCYP2C19POLB | |
| Benzamide SCHEMBL11668921 | 0.89 | PARP1 (1.00) | PARP1TDP1TSHRCYP2C19POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0201537-B1 | NOVEL USE OF ANTI-NAUSEA AND ANTI-EMETIC PHARMAZEUTICAL AGENTS. | NASTECH PHARMACEUTICAL COMPANY, INC. (US) | 1992-04-29 | — | — | EP | claimed |
| US-20250288678-A1 | DOSAGES OF IMMUNOCONJUGATES OF ANTIBODIES AND SN-38 FOR IMPROVED EFFICACY AND DECREASED TOXICITY | IMMUNOMEDICS, INC. | 2025-09-18 | — | — | US | disclosed |
| US-20180064825-A1 | ANTI-PD-L1 IMMUNOTOXIN FOR USE IN THERAPY | UNIVERSITE D'AIX-MARSEILLE (FR) | 2018-03-08 | — | — | US | disclosed |
| EP-3280439-A1 | ANTI-PD-L1 IMMUNOTOXIN FOR USE IN THERAPY | INSERM - Institut National de la Santé et de la Recherche Médicale (FR) | 2018-02-14 | — | — | EP | disclosed |
| WO-2016162356-A1 | ANTI-PD-L1 IMMUNOTOXIN FOR USE IN THERAPY | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2016-10-13 | — | — | WO | disclosed |
| US-20160151489-A1 | COMBINATION OF A LIGAND OF HVEM AND AN IMMUNOTOXIN FOR USE IN THERAPY | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2016-06-02 | — | — | US | disclosed |
| EP-3022227-A1 | COMBINATION OF A LIGAND OF HVEM AND AN IMMUNOTOXIN FOR USE IN THERAPY | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2016-05-25 | — | — | EP | disclosed |
| WO-2015007887-A1 | COMBINATION OF A LIGAND OF HVEM AND AN IMMUNOTOXIN FOR USE IN THERAPY | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2015-01-22 | — | — | WO | disclosed |
| EP-0625967-B1 | N,N'-SUBSTITUTED IMIDOCARBONIMIDIC DIAMIDES DERIVED FROM HYDROXYLAMINES | JACOBUS PHARMA CO INC (US) | 1997-08-27 | — | — | EP | disclosed |
| EP-0625967-A1 | N,N'-SUBSTITUTED IMIDOCARBONIMIDIC DIAMIDES DERIVED FROM HYDROXYLAMINES. | JACOBUS PHARMA CO INC (US) | 1994-11-30 | — | — | EP | disclosed |
| US-5322858-A | Antimicrobial, antiparasitic agents | JACOBUS PHARMACEUTICAL CO. INC. (US) | 1994-06-21 | — | — | US | disclosed |
| WO-1993016037-A1 | N,N'-SUBSTITUTED IMIDOCARBONIMIDIC DIAMIDES DERIVED FROM HYDROXYLAMINES | JACOBUS PHARMACEUTICAL CO., INC. (US) | 1993-08-19 | — | — | WO | disclosed |
| EP-0422134-A4 | 5-HT SELECTIVE AGENTS | — | 1992-05-06 | — | — | EP | disclosed |
| US-4083868-A | INTRAOCULAR PRESSURE LOWERING AGENTS | ABBOTT LABORATORIES (US) | 1978-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250288678-A1 | DOSAGES OF IMMUNOCONJUGATES OF ANTIBODIES AND SN-38 FOR IMPROVED EFFICACY AND DECREASED TOXICITY | ERBB3, ERBB2, NTRK1 | PARP1 562/4885TDP1 1072/4885TSHR 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.